Olema Oncology to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Olema Oncology (Nasdaq: OLMA) announced participation in three investor conferences in February 2026: Guggenheim Emerging Outlook: Biotech Summit on Feb 11 (New York, fireside chat), Citi’s Virtual Oncology Leadership Summit on Feb 19 (virtual, fireside chat), and Oppenheimer Healthcare Life Sciences on Feb 26 (virtual, fireside chat). Live webcasts and recordings will be posted at Olema's investor relations site, as permitted by event hosts.

SAN FRANCISCO, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company will participate in the following upcoming investor conferences:

Guggenheim Securities Emerging Outlook: Biotech Summit
Date and Time: February 11, 2026 at 10:00 a.m. ET
Format: Fireside Chat
Location: New York, NY

Citi’s 2026 Virtual Oncology Leadership Summit
Date and Time: February 19, 2026 at 1:00 p.m. ET
Format: Fireside Chat
Location: Virtual

Oppenheimer 36^th Annual Healthcare Life Sciences Conference
Date and Time: February 26, 2026 at 8:00 a.m. ET
Format: Fireside Chat
Location: Virtual

Live webcasts and recordings of these presentations will be available, as permitted by the event host, in the Events and Presentations section of Olema’s investor relations website at ir.olema.com.

About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging our deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Our lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), currently in two Phase 3 clinical trials. In addition, Olema is developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor, now in a Phase 1 clinical study. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts. For more information, please visit www.olema.com.

Media and Investor Relations Contact
Courtney O’Konek
Vice President, Corporate Communications
Olema Oncology
media@olema.com

FAQ

When will Olema Oncology (OLMA) present at the Guggenheim Emerging Outlook: Biotech Summit?

Olema will present on February 11, 2026 at 10:00 a.m. ET, in a fireside chat format. According to the company, the session takes place in New York and may be available via webcast or recording on the investor relations website if permitted by the event host.

How can investors watch Olema Oncology (OLMA) at Citi’s 2026 Virtual Oncology Leadership Summit?

Olema is scheduled for a fireside chat on February 19, 2026 at 1:00 p.m. ET in virtual format. According to the company, live webcast access and recordings may be available on the investor relations site, subject to permission from the event host.

What are the details for Olema Oncology's (OLMA) Oppenheimer conference presentation on February 26, 2026?

Olema will present on February 26, 2026 at 8:00 a.m. ET in a fireside chat, delivered virtually. According to the company, the presentation may be webcast and archived on the investor relations page, contingent on the event host's permission.

Where can I find webcasts and recordings of OLMA presentations from February 2026 conferences?

Webcasts and recordings will be posted in the Events and Presentations section of Olema's investor relations website at ir.olema.com, as permitted by each event host. According to the company, availability depends on host permissions and event-specific distribution rules.

What topics will Olema Oncology (OLMA) likely cover during the February 2026 investor conference fireside chats?

Presentations will focus on the company's clinical-stage programs and strategic outlook, delivered in fireside chat format. According to the company, the sessions are intended to update investors on development programs and corporate strategy, with specifics provided during each event.